<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Recash test site | Saunders Mahoney | Activity</title>
	<link>https://recash.wpsoul.net/members/liquorqueen38/activity/</link>
	<atom:link href="https://recash.wpsoul.net/members/liquorqueen38/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Saunders Mahoney.</description>
	<lastBuildDate>Thu, 21 May 2026 06:44:37 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">59c44ad4195a4ac9382b504ac7eef892</guid>
				<title>Saunders Mahoney posted an update: Four (3.8%) and 7 (6.8%) patients in the D-RVd and RVd groups [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/57386/</link>
				<pubDate>Thu, 12 Dec 2024 06:24:53 +0000</pubDate>

									<content:encoded><![CDATA[<p>Four (3.8%) and 7 (6.8%) patients in the D-RVd and RVd groups progressed, respectively, and 24-month progression-free survival rates were 95.8% (D-RVd) and 89.8% (RVd). Grade 3/4 hematologic adverse events were more common with D-RVd. More infections occurred with D-RVd, but rates of grade 3/4 infections were similar. Median CD34+ cell yield was&hellip;<span class="activity-read-more" id="activity-read-more-57386"><a href="https://recash.wpsoul.net/activity/p/57386/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7859fc3bde67094d33215b1b661c7d42</guid>
				<title>Saunders Mahoney became a registered member</title>
				<link>https://recash.wpsoul.net/activity/p/57332/</link>
				<pubDate>Thu, 12 Dec 2024 06:09:19 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>